The Biotech BuySider's Guide To Investor Relations
David Sable (Forbes)
Drug Projected at $1 Million Has Spark Mulling Installment Plan
Caroline Chen (Bloomberg) $ONCE
Pharmaceutical Companies Race to Build CAR T-Cell Manufacturing Processes
Tim Taga (Genetic Engineering News) $JUNO
Here's A Colossally Bad Idea From Congress About How To Fund Science
Steven Salzberg (Forbes)
The Other Side of the Fence
Ron Renaud (LifeSciVC)
Fight looms over practice that forces patients to wait for better prescription drugs
Kathleen McGrory (Tampa Bay Times)
NantKwest IPO and Roadshow Review
Robert Kruse (Biotechr) $NK
Pharma Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure
Paul Barrett and Robert Langreth (Bloomberg) $GILD
David Sable (Forbes)
Drug Projected at $1 Million Has Spark Mulling Installment Plan
Caroline Chen (Bloomberg) $ONCE
Pharmaceutical Companies Race to Build CAR T-Cell Manufacturing Processes
Tim Taga (Genetic Engineering News) $JUNO
Here's A Colossally Bad Idea From Congress About How To Fund Science
Steven Salzberg (Forbes)
The Other Side of the Fence
Ron Renaud (LifeSciVC)
Fight looms over practice that forces patients to wait for better prescription drugs
Kathleen McGrory (Tampa Bay Times)
NantKwest IPO and Roadshow Review
Robert Kruse (Biotechr) $NK
Pharma Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure
Paul Barrett and Robert Langreth (Bloomberg) $GILD
RSS Feed
